ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1224

Rheumatoid Arthritis Disease Activity During Pregnancy Affects the Postnatal Catch-up Growth of the Child

Florentien D.O. de Steenwinkel1, Anita C.S. Hokken-Koelega2, Maria A.J. de Ridder3, Johanna M.W. Hazes4 and Radboud J.E.M. Dolhain1, 1Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, 3Bio Statistics, Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: prednisolone, prednisone and pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Active rheumatoid arthritis (RA) during pregnancy is associated with lower birth weight. Active RA during pregnancy can be treated with prednisone. However, studies have shown that prednisone use during pregnancy reduces gestational age thereby indirectly creates lower birth weight1. In general, newborns with a lower birth weight will catch-up in growth after they are born. Literature shows that a fast catch-up growth pattern of the child is associated with cardiovascular risk and metabolic disorders in early adulthood2.  The purpose of this study: “Is maternal RA and/or prednisone use during pregnancy associated with fast catch-up growth in the first 2 years of the child?”

Methods:  Current study is a continuation of a prospective nationwide study on RA during pregnancy. Growth charts were collected from children born from mothers participating in this study. Dependent variable: height standard deviation score (SDS) and weight SDS on different time points. Independent variable: prednisone use and RA disease activity (DAS28) during pregnancy.

Results: 161 growth charts were analyzed; 67 women used prednisone at some point during their pregnancy. The mean DAS28 during pregnancy was significantly higher in the prednisone group, 3.88 (SD: 1.01) than in the group without prednisone 3.02 (SD: 1.03) (p<0.0001).

An association was found between elevated DAS28 during pregnancy and fast catch-up growth (>0.50 SDS) of the child within the first half year. An increase of one point DAS28 during pregnancy resulted in a catch-up weight of 0.16 (p=0.03) and a catch-up height of 0.12 (p=0.04) at the age of 3 months. No effect was shown for prednisone use.

Conclusion: Our study suggests that elevated RA disease activity during pregnancy is associated with fast catch-up growth. This might have lifelong consequences for the child. Minimizing the disease activity during pregnancy is therefore crucial and should be striven at all times.

1.            de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. Nov 2009;60(11):3196-3206.

2.            Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. JAMA. Jun 3 2009;301(21):2234-2242.


Disclosure:

F. D. O. de Steenwinkel,
None;

A. C. S. Hokken-Koelega,
None;

M. A. J. de Ridder,
None;

J. M. W. Hazes,
None;

R. J. E. M. Dolhain,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-disease-activity-during-pregnancy-affects-the-postnatal-catch-up-growth-of-the-child/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology